Frequency of Intra-Articular Betamethasone Injections to the Knee
Limit betamethasone injections to the knee to no more than 3-4 injections per year, with a minimum interval of 3 months between injections. 1
Evidence-Based Frequency Guidelines
The 2021 EULAR recommendations provide the most authoritative guidance on this topic. The generally accepted rule is to avoid more than 3-4 glucocorticoid injections in the same joint per year 1, though this recommendation acknowledges it is based on expert consensus rather than high-quality research evidence.
Minimum Interval Between Injections
- 3 months is the standard minimum interval between repeat injections 1
- This interval is supported by RCT data showing that injections every 3 months for 2 years can be performed, though with conflicting results on cartilage effects 1
- Survey data from American orthopedic surgeons confirms that the 3-month interval is the most commonly used minimum, though many prefer longer intervals 2
Important Nuances in the Evidence
The EULAR guidelines acknowledge a critical limitation: "high-quality studies that aimed to evaluate the long-term effect of repeating IA injections are scarce" 1. Two RCTs comparing glucocorticoid injections every 3 months for 2 years showed contradictory findings:
- One demonstrated symptom improvement with no cartilage damage
- The other showed no pain benefit and greater cartilage volume loss 1
This conflicting evidence underscores the need for caution with frequent repeat injections.
Dosing Information from FDA Label
For knee injections specifically, the FDA-approved betamethasone label recommends 1 mL for large joints like the knee 3. The label does not specify maximum frequency, deferring to clinical judgment.
Special Considerations and Precautions
Before Surgery
- Wait at least 3 months between the last injection and total knee arthroplasty 1
- Injections within 0-3 months before surgery show slightly increased infection rates (0.5% to 1.0% vs background 1.04% to 2.5%) 1
- Multiple cumulative injections beyond the 90-day window do not increase periprosthetic infection risk 4
In Diabetic Patients
- Monitor blood glucose levels closely for days 1-3 post-injection 1
- Transient hyperglycemia is expected but serious complications (ketoacidosis, hyperosmolar state) are rare 1
- Diabetes is not a contraindication to injection 1
Decision to Re-inject
The decision to repeat injections should be individualized based on:
- Response to previous injections
- Available treatment alternatives
- Systemic treatment status
- Patient comorbidities 1
Post-Injection Care
- Avoid overuse of the injected joint for 24 hours, but do not immobilize 1
- Immobilization (splinting, bed rest) provides no additional benefit 1
Common Pitfalls to Avoid
- Injecting too frequently: Respect the 3-month minimum interval to minimize potential cartilage damage risk
- Injecting close to planned surgery: The 3-month preoperative window reduces infection risk
- Failing to monitor diabetics: Blood glucose monitoring is essential in the first 72 hours
- Exceeding 4 injections per year: While not an absolute contraindication, this increases theoretical risks without clear evidence of sustained benefit